{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:40:05Z","timestamp":1788871205257,"version":"build-2803163510"},"reference-count":79,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.clbc.2014.03.002","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T13:04:22Z","timestamp":1401887062000},"page":"297-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor\u2013Positive Advanced Breast Cancer: Considerations for Oncologists"],"prefix":"10.1016","volume":"14","author":[{"given":"Denise A.","family":"Yardley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2014.03.002_bib1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2014.03.002_bib2","unstructured":"National Cancer Institute. SEER Statistic Fact Sheet: Breast Cancer 2013. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/breast.html. Accessed: November 7,\u00a02013."},{"key":"10.1016\/j.clbc.2014.03.002_bib3","series-title":"Cancer Facts and Figures\u00a02014","author":"American Cancer Society","year":"2014"},{"key":"10.1016\/j.clbc.2014.03.002_bib4","series-title":"Breast Cancer Facts and Figures: 2011-2012","author":"American Cancer Society","year":"2012"},{"key":"10.1016\/j.clbc.2014.03.002_bib5","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/aje\/kwp036","article-title":"Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study","volume":"169","author":"Setiawan","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clbc.2014.03.002_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1020299707510","article-title":"Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database","volume":"76","author":"Anderson","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2014.03.002_bib7","series-title":"Arimidex anastrozole tablets. [prescribing information]","year":"2004"},{"key":"10.1016\/j.clbc.2014.03.002_bib8","series-title":"Femara letrozole tablets. 2.5 mg tablets [prescribing information]","year":"2006"},{"key":"10.1016\/j.clbc.2014.03.002_bib9","series-title":"Aromasin exemestane tablets. [prescribing information]","year":"2004"},{"key":"10.1016\/j.clbc.2014.03.002_bib10","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. version 1.2014. Available at: http:\/\/www.nccn.org\/patients\/guidelines\/stage_iv_breast\/files\/assets\/basic-html\/index.html#1. Accessed: March 2, 2014."},{"key":"10.1016\/j.clbc.2014.03.002_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10549-010-0974-0","article-title":"Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer","volume":"123","author":"Riemsma","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2014.03.002_bib12","doi-asserted-by":"crossref","unstructured":"Cardoso F, Senkus-Konefka E, Fallowfield L, et\u00a0al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol; 21 (suppl 5):v15\u221219.","DOI":"10.1093\/annonc\/mdq160"},{"key":"10.1016\/j.clbc.2014.03.002_bib13","series-title":"Nolvadex tamoxifen citrate [prescribing information]","year":"2005"},{"key":"10.1016\/j.clbc.2014.03.002_bib14","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","article-title":"Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial","volume":"22","author":"Howell","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib15","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1200\/JCO.2008.21.1136","article-title":"Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study","volume":"27","author":"Robertson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib16","series-title":"Faslodex fulvestrant injection [prescribing information]","year":"2004"},{"key":"10.1016\/j.clbc.2014.03.002_bib17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.breast.2006.01.007","article-title":"Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors","volume":"15","author":"Dodwell","year":"2006","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2014.03.002_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/bcr2931","article-title":"Understanding the mechanisms of aromatase inhibitor resistance","volume":"14","author":"Miller","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2014.03.002_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clbc.2012.11.002","article-title":"Changing concepts of hormone receptor-positive advanced breast cancer therapy","volume":"13","author":"Chlebowski","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2014.03.002_bib20","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-09-1823","article-title":"New strategies in estrogen receptor-positive breast cancer","volume":"16","author":"Johnston","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2014.03.002_bib21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2014.03.002_bib22","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1158\/0008-5472-CAN-04-3913","article-title":"PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma","volume":"65","author":"Saal","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2014.03.002_bib23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4161\/cc.3.10.1164","article-title":"Oncogenic mutations of PIK3CA in human cancers","volume":"3","author":"Samuels","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clbc.2014.03.002_bib24","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","article-title":"Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity","volume":"10","author":"deGraffenried","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2014.03.002_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10549-010-1315-z","article-title":"Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer","volume":"126","author":"Kim","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2014.03.002_bib26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/sj.bjc.6600126","article-title":"Activation of AKT\/PKB in breast cancer predicts a worse outcome among endocrine treated patients","volume":"86","author":"Perez-Tenorio","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2014.03.002_bib27","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-010-0986-9","article-title":"\u201cOvercoming breast cancer drug resistance with mTOR inhibitors.\u201d Could it be a myth or a real possibility in the short-term future?","volume":"128","author":"Margariti","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 3","key":"10.1016\/j.clbc.2014.03.002_bib29","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.3816\/CBC.2010.s.013","article-title":"Deciphering the role of PI3K\/Akt\/mTOR pathway in breast cancer biology and pathogenesis","volume":"10","author":"McAuliffe","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2014.03.002_bib30","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","article-title":"Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer","volume":"27","author":"Baselga","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib31","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib32","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2014.03.002_bib33","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.clbc.2014.03.002_bib34","unstructured":"US Food and Drug Administration. FDA approves Afinitor for advanced breast\u00a0cancer. [FDA news release]. July 20, 2012. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm312965.htm. Accessed: November 7,\u00a02013."},{"key":"10.1016\/j.clbc.2014.03.002_bib35","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/cncr.28010","article-title":"Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial","volume":"119","author":"Burris","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2014.03.002_bib36","series-title":"Torisel temsirolimus. injection [prescribing information]","year":"2008"},{"key":"10.1016\/j.clbc.2014.03.002_bib37","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features","volume":"19","author":"Bellmunt","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib38","unstructured":"Merck & Co.,Inc. NDA 22-576 ridaforolimus tablets. oncologic drugs advisory committee briefing document. 2012 Mar. Report No.: ODAC Briefing Document. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM296305.pdf. Accessed: November 26,\u00a02013."},{"key":"10.1016\/j.clbc.2014.03.002_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11523-009-0107-z","article-title":"The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents","volume":"4","author":"Sankhala","year":"2009","journal-title":"Target Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1399-0012.2010.01232.x","article-title":"mTOR inhibitor-associated dermatologic and mucosal problems","volume":"24","author":"Campistol","year":"2010","journal-title":"Clin Transplant"},{"key":"10.1016\/j.clbc.2014.03.002_bib41","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/00007890-200004150-00009","article-title":"Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients","volume":"69","author":"Kreis","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.clbc.2014.03.002_bib42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2014.03.002_bib43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2014.03.002_bib44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex EXIST-1.: a multicenter, randomized, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2014.03.002_bib45","series-title":"Afinitor everolimus tablets for oral administration [prescribing information]","year":"2014"},{"key":"10.1016\/j.clbc.2014.03.002_bib46","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis EXIST-2.: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2014.03.002_bib47","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","article-title":"Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients","volume":"116","author":"Sonis","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2014.03.002_bib48","doi-asserted-by":"crossref","unstructured":"Perez A, Rugo HS, Baselga J, et\u00a0al. Clinical management and resolution of stomatitis in BOLERO-2. Poster presented at 49th Annual Meeting of the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago, IL.","DOI":"10.1200\/jco.2013.31.26_suppl.159"},{"key":"10.1016\/j.clbc.2014.03.002_bib49","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejca.2011.06.054","article-title":"An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy","volume":"48","author":"Grunwald","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2014.03.002_bib50","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.oraloncology.2011.08.009","article-title":"Clinical presentation and management of mTOR inhibitor-associated stomatitis","volume":"47","author":"de Oliveira","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib51","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.ejca.2011.03.017","article-title":"Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues","volume":"47","author":"Ferte","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2014.03.002_bib52","unstructured":"Divers J. Management of stomatitis associated with mTOR inhibitors in hormone receptor-positive\/HER-2 negative advanced breast cancer: clinical experience from a single center. Poster presented at 38th Annual Oncology Nurses' Society Congress; April 25-28, 2013; Washington, DC."},{"key":"10.1016\/j.clbc.2014.03.002_bib53","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1188\/11.CJON.E83-E89","article-title":"Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors","volume":"15","author":"Pilotte","year":"2011","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clbc.2014.03.002_bib54","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","article-title":"Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma","volume":"47","author":"Porta","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2014.03.002_bib55","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1016\/j.oooo.2013.02.022","article-title":"Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management","volume":"116","author":"Nicolatou-Galitis","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.clbc.2014.03.002_bib56","first-page":"51","article-title":"Management of key adverse events associated with everolimus therapy","volume":"8","author":"Moldawer","year":"2010","journal-title":"Kidney Cancer J"},{"key":"10.1016\/j.clbc.2014.03.002_bib57","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1002\/cncr.27505","article-title":"Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors","volume":"118","author":"Balagula","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2014.03.002_bib58","unstructured":"National Cancer Institute. Common terminology criteria for adverse events v3.0 CTCAE. National Cancer Institute Web site, 2006 August 9; v3.0.:1-72. Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed: September 13,\u00a02013."},{"key":"10.1016\/j.clbc.2014.03.002_bib59","unstructured":"Agricola K, Tudor C, Krueger DA, et\u00a0al. First approved targeted medical therapy for subependymal giant-cell astrocytoma in patients with tuberous sclerosis complex: strategies to improve tolerability and patient outcomes by effective management of side effects. Presented at the 43rd Annual Educational Meeting American Association of Neuroscience Nurses; March 19-22, 2011; Kansas City, MO."},{"key":"10.1016\/j.clbc.2014.03.002_bib60","doi-asserted-by":"crossref","unstructured":"Ito Y, Noguchi S, Deleu I, et\u00a0al. Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2. Poster presented at the 49th Annual Meeting of the American Society for Clinical Oncology; May 31-June 4, 2013; Chicago, IL.","DOI":"10.1200\/jco.2013.31.26_suppl.159"},{"key":"10.1016\/j.clbc.2014.03.002_bib61","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND.163","volume":"27","author":"Ellard","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib62","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/JTO.0b013e3181ba20b1","article-title":"Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus RAD001","volume":"4","author":"White","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib63","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clbc.2014.03.002_bib64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/IJNRD.S4191","article-title":"The use of everolimus in renal-transplant patients","volume":"2","author":"Pascual","year":"2009","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.clbc.2014.03.002_bib65","unstructured":"Rugo HS, Gnant M, Geberth M, et\u00a0al. Everolimus-related adverse events: safety insights from BOLERO-2. Presented at St. Gallen International Breast Cancer Conference; March 13-16, 2013; St. Gallen, Switzerland."},{"key":"10.1016\/j.clbc.2014.03.002_bib66","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrclinonc.2012.1","article-title":"Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer","volume":"9","author":"Torres","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib67","unstructured":"Shiah HS, Chen CY, Hsiao CF, et\u00a0al. Randomized, phase I study of everolimus in patients with advanced hepatocellular carcinoma. Poster presented at 12th World Conference on Gastrointestinal Cancers; June 30-July 3, 2010; Barcelona, Spain."},{"key":"10.1016\/j.clbc.2014.03.002_bib68","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1002\/cncr.26165","article-title":"Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2014.03.002_bib69","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","article-title":"Common toxicities of mammalian target of rapamycin inhibitors","volume":"6","author":"Soefje","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib70","series-title":"Tips for managing treatment-related rash\u00a0and dry skin","author":"Fleishman","year":"2012"},{"key":"10.1016\/j.clbc.2014.03.002_bib71","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.03.002_bib72","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clbc.2014.03.002_bib73","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc12-s011","article-title":"Standards of medical care in diabetes: 2012","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clbc.2014.03.002_bib74","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC)","volume":"32","author":"Europea Association for Cardiovascular Prenvention & Rehabilitation","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clbc.2014.03.002_bib75","first-page":"567","article-title":"2009 Canadian Cardiovascular Society\/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult\u20142009 recommendations","volume":"25","author":"Genest","year":"2009","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.clbc.2014.03.002_bib76","unstructured":"National Institutes of Health, National Heart, Lung, and Blood Institute. US Detection, evaluation, and treatment of high blood cholesterol in adults adult treatment panel III. Final report. Bethesda, MD, Department of Health and Human Services. National Institutes of Health, September 2002. NIH publication 02-5215."},{"key":"10.1016\/j.clbc.2014.03.002_bib77","first-page":"107180","article-title":"A\u00a0prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation","volume":"2012","author":"Kasiske","year":"2012","journal-title":"J\u00a0Transplant"},{"key":"10.1016\/j.clbc.2014.03.002_bib78","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0041-1345(00)02116-3","article-title":"Comparison of the in\u00a0vitro metabolism of the macrolide immunosuppressants sirolimus and RAD","volume":"33","author":"Jacobsen","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1016\/j.clbc.2014.03.002_bib79","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820914000846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820914000846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:13:22Z","timestamp":1761513202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820914000846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1526820914000846"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2014.03.002","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor\u2013Positive Advanced Breast Cancer: Considerations for Oncologists","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2014.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}